Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, UK.
Curr Vasc Pharmacol. 2011 Sep;9(5):533-71. doi: 10.2174/157016111796642661.
Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density liproproteins (LDL) subclasses. We sub-divided our statement in 2 sections. section I discusses the pathophysiology, atherogenicity and measurement issues, while section II is focused on the effects of drug and lifestyle modifications. Suggestions for future research in the field are highlighted at the end of section II. Each section includes Conclusions.
本共识声明的目的是提供一份全面而最新的关于低密度脂蛋白（LDL）亚类的病理生理学、致动脉粥样硬化性和临床意义的文件。我们将声明分为两部分。第 I 节讨论病理生理学、致动脉粥样硬化性和测量问题，而第 II 节则侧重于药物和生活方式改变的效果。在第 II 节的结尾，突出了该领域未来研究的建议。每一节都包括结论。
